消风宣窍汤对小鼠变应性鼻炎模型效应机制研究

陶嘉磊; 汪受传; 姜茗宸; 戴启刚

消风宣窍汤对小鼠变应性鼻炎模型效应机制研究

江苏省儿童呼吸疾病中医药重点实验室，南京中医药大学中医儿科学研究所，江苏南京 210023

计量
- 文章访问数: 1386
- HTML全文浏览量: 12
- PDF下载量: 1142
- 被引次数: 0
出版历程
- 收稿日期: 2016-11-15
- 修回日期: 2016-12-30
- 刊出日期: 2017-03-10

Acting Mechanism of Xiaofeng Xuanqiao Decoction for on Mice Model of Allergic Rhinitis

摘要

摘要: 目的探讨消风宣窍汤对变应性鼻炎（AR）小鼠治疗效应及其相关机制。方法 48只BALB/c小鼠随机分为正常组，模型组，消风宣窍汤组，孟鲁斯特组，每组12只。采用OVA致敏建立小鼠AR模型。灌胃治疗1周，观测小鼠鼻部症状积分，体质量、胸腺和脾脏质量及指数，鼻黏膜组织学改变，血清总IgE、OVA特异性IgE以及胸腺IL-4、IL-17、IL-33、IFN-γ水平。结果消风宣窍汤能够显著降低AR小鼠鼻部症状，减轻变应性反应引起的体质量、胸腺质量、胸腺指数的增加，能够显著减少血清总IgE、OVA特异性IgE的水平，抑制胸腺IL-4、IL-17、IL-33、IFN-γ产生，且在降低胸腺IL-33水平方面，消风宣窍汤效果优于西药孟鲁斯特组。结论消风宣窍汤对AR小鼠疗效确切，其可能通过抑制胸腺细胞因子水平发挥抗AR效应。
- 消风宣窍汤 /
- 变应性鼻炎 /
- 小鼠 /
- 胸腺 /
- 细胞因子
Abstract: OBJECTIVE To investigate the therapeutic effects of Xiaofeng Xuanqiao Decoction in treating mice with allergic rhinitis(AR) as well as its mechanism. METHODS 48 BALB/c mice were randomly divided into normal group， model group， Xiaofeng Xuanqiao Decoction group and montelukast group， with 12 mice in each group. OVA sensitized mice were established as the model with gavage for 1 week. Nasal symptom scores， weight， weight of thymus and spleen index， nasal mucosa changes， serum total IgE， ova specific IgE and IL-4， IL-17， IL-33， IFN-γ levels in the thymus of mice were observed. RESULTS Xiaofeng Xuanqiao Decoction could significantly reduce nasal symptoms of AR in mice， reduce the increased weight， thymus weight and thymus index caused by allergic reaction. Besides， it could significantly reduce serum total IgE and ova specific IgE level， and inhibit the production of thymus IL-4， IL-17， IL-33， IFN-γ. In reducing the thymus IL-33 level， Xiaofeng Xuanqiao decoction was better than western medicine montelukast group. CONCLUSION Xiaofeng Xuanqiao Decoction has definite effects for AR in mice. The anti AR effects can be achieved by inhibiting the level of thymic cytokine.
- Xiaofeng Xuanqiao decoction /
- allergic rhinitis /
- mice /
- thymus /
- cytokine

HTML全文

参考文献(20)

[1]	PAWANKAR R， MORI S， OZU C， et al. Overview on the pathomechanisms of allergic rhinitis[J]. Asia Pac Allergy， 2011， 1(3): 157-167.
[2]	陶嘉磊．汪受传从伏邪学说论治小儿支气管哮喘经验[J]．中医杂志，2015， 56（23）：1996-1998．
[3]	TAO JL. Experience of WANG shouchuan in treating pediatric bronchial asthma based on theory of latent evil[J]. J Tradit Chin Med， 2015， 56(23): 1996-1998.
[4]	李萌．汪受传教授从伏风论治小儿鼻鼽经验总结及机理研究[D]．南京：南京中医药大学，2014．
[5]	LI M. Professor WANG Shou-chuan's experience and mechanism research in treating pediatric Bi Qiu from latent wind[D]. Nanjing: Nanjing University of Chinese Medicine， 2014.
[6]	KIM EH， KIM JH， SAMIVEL R， et al. Intralymphatic treatment of flagellin-ovalbumin mixture reduced allergic inflammation in murine model of allergic rhinitis[J]. Allergy， 2016， 71(5): 629-639.
[7]	ALM B， GOKSOR E， PETTERSSON R， et al. Antibiotics in the first week of Life is a risk factor for allergic rhinitis at school age[J]. Pediatr Allergy Immunol， 2014， 25(5): 468-472.
[8]	李萌，徐珊，汪受传. 汪受传教授从伏风论治小儿鼻鼽经验[J]. 中华中医药杂志， 2013(11):3278-3280.
[9]	LI M， XU S， WANG SC. Professor WANG Shou-chuan's experience in treating pediatric allergic rhinitis from latent wind[J]. China J Tradit Chin Med Pharm， 2013，28(11):3278-3280.
[10]	李萌，戴启刚．汪受传教授治疗小儿鼻鼽药对经验[J]．中医儿科杂志，2013， 9（2）：1-2．
[11]	LI M， DAI QG. Experience of professor Wang shouchuan's treatment of pediatric allergic rhinitis with paired medicine[J]. J Pediatr Tradit Chin Med， 2013， 9(2): 1-2.
[12]	HIJNEN D， DE BRUIN-WELLER M， OOSTING B， et al. Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell- attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis[J]. J Allergy Clin Immunol， 2004， 113(2): 334-340.
[13]	王文婕，王晓川，章迁，等．小鼠哮喘模型胸腺中胸腺基质淋巴生成素、Foxp3的表达及调节[J]．中国循证儿科杂志，2008， 3（4）：292-297．
[14]	WANG WJ， WANG XC， ZHANG Q， et al. Expression and modulation of TSLP， Foxp3 in central immune organ (thymus) in mice asthma model[J]. Chin J Evid Based Pediatr， 2008， 3(4): 292-297.
[15]	KORN T， BETTELLI E， OUKKA M， et al. IL-17 and Th17 cells[J]. Annu Rev Immunol， 2009， 27(1): 485-517.
[16]	CIPRANDI G， DE AMICI M， MURDACA G， et al. Serum interleukin-17 levels are related to clinical severity in allergic rhinitis[J]. Allergy， 2009， 64(9): 1375-1378.
[17]	LI H， XU E， HE M. Cytokine responses to specific immunotherapy in house dust Mite-Induced allergic rhinitis patients[J]. Inflammation， 2015， 38(6): 2216-2223.
[18]	SUZUKAWA M， LIKURA M， KOKETSU R， et al. An IL-1 cytokine member， IL-33， induces human basophil activation via its ST2 receptor[J]. J Immunol， 2008， 181(9): 5981-5989.
[19]	DIVEKAR R， KITA H. Recent advances in epithelium-derived cytokines (IL-33， IL-25， and thymic stromal lymphopoietin) and allergic inflammation[J]. Curr Opin Allergy Clin Immunol， 2015， 15(1): 98-103.
[20]	HAENUKI Y， MATSUSHITA K， FUTATSUGI-YUMIKURA S， et al. A critical role of IL-33 in experimental allergic rhinitis[J]. J Allergy Clin Immunol， 2012， 130(1): 184-194.e11.